Halozyme Therapeutics HALO Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total liabilities?
- Halozyme Therapeutics (HALO) reported total liabilities of $2.45B in Q1 2026.
- How has Halozyme Therapeutics's total liabilities changed year-over-year?
- Halozyme Therapeutics's total liabilities increased by 43.1% year-over-year, from $1.71B to $2.45B.
- What is the long-term trend for Halozyme Therapeutics's total liabilities?
- Over 3 years (2022 to 2025), Halozyme Therapeutics's total liabilities has grown at a 14.0% compound annual growth rate (CAGR), from $1.67B to $2.48B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.